|
(MoneyNewsWire.Net, August 18, 2017 ) The Global Liquid Biopsy market is expected to increase at a CAGR of 24.3% in the forecast period of 2016-2021 and reach a value of USD 1.75 billion by 2021 from USD 590.2 million in 2016.
This technology of Liquid Biopsy Market Share has enormous diagnostic and treatment implications for oncology and it is believed to transform clinical practice. A liquid biopsy, may capture the entire heterogeneity of the disease. This methodology is advantageous over tissue biopsies as monitoring of tumour genomic can be done by taking serial samples.
Browse market data tables and in-depth TOC of the Global Liquid Biopsy Industry to 2021 @ http://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/
Foremost drivers for the liquid biopsy market include. Liquid biopsies are adopted due to the factors such as tolerability and patient convenience. Tissue biopsies cannot be done for few non-small cell lung cancers and liquid biopsy procedures are replacing tissue diagnosis procedures in such cases. Liquid biopsy research process involves a large amount of money and frequent clinical trials which is acting as a restraint for the market growth.
Free sample of the report is available @ http://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/request-sample
0054he liquid biopsy market is mainly segmented by types of cancer into Lung Cancer, Pancreatic Cancer, Leukemia and Other Visceral Cancers. By Diagnostic approach they can be classified as Circulating Tumour cells (CTC), Circulating Tumour DNA (ctDNA), RNA in exosomes and Extra-Cellular Vesicles. Based on end users, the market is segmented into reference laboratories, hospital/physician laboratories, academic and research centers, and other end users. The market is bifurcate into blood, urine, plasma, saliva and Cerebrospinal fluid based upon sample type. CTCs (Circulating Tumour cells), the first such entities on the liquid biopsy scene, have accounted for a large share in the market. Cancer institute is the largest end user segment in terms of revenues and is expected to create substantial opportunity in global liquid biopsy market over the forecast period.
Geographically the market is segmented into North America (U.S.A. and Canada), Europe (U.K., Germany, Italy, France, and Spain), Asia-Pacific (India, China, Australia, South Korea and Japan), Latin America (Mexico, Argentina and Brazil), Middle East and Africa. All major action in the field of liquid biopsy is expected to emerge from North America and Europe region over the forecast period. However, increasing funding for private public partnerships in field of cancer research is expected to fuel the Asia-Pacific Market.
Inquire before Buying at http://www.marketdataforecast.com/market-reports/global-liquid-biopsy-market-950/inquire
The key players dominating the liquid biopsy market are Janssen Diagnostics, Qiagen, Rarecells SAS, Silicon Biosystems, SRI International, Myriad Genetics, Natera, Personal Genome Diagnostics, Sysmex Inostics, Trovagene, Exosome Diagnostics, Exosome Sciences, and HansaBiomed OU.
About Us:
Market Data Forecast is a firm working in the area of market research and business intelligence. With rich experience in research across various business domains, we cater to the needs of both individual and corporate clients. Our analyst team comprises expert professionals in market research, who with their collective knowledge and skillset dedicatedly serve clients from various industries and regions.
Visit Market Data Forecast Blog @ http://www.marketdataforecast.com/blog/
View latest Press Releases of MDF @ http://www.marketdataforecast.com/press-releases
Market Data Forecast
Abhishek
+1-888- 702-9626
abhishek@marketdataforecast.com
Source: EmailWire.Com 
|
